• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 21 of 100
Diabetes drug Ozempic
Magazine
Novo Nordisk developed Ozempic and started a weight-loss revolution. Its next moonshot is eliminating obesity altogether
By Vivienne WaltJuly 31, 2023
Ozempic manufacturer Novo Nordisk spent $11 million last year ‘wining and dining’ doctors. Experts slam the move as a breach of doctor-patient trust
Health
Ozempic manufacturer Novo Nordisk spent $11 million last year ‘wining and dining’ doctors. Experts slam the move as a breach of doctor-patient trust
By Erin PraterJuly 21, 2023
Digitalization could be the answer to better health care for patients. But first, they need to trust it
Newsletters
Digitalization could be the answer to better health care for patients. But first, they need to trust it
By Eamon BarrettJuly 21, 2023
Biden administration pushes Walgreens, CVS and Walmart to tout drug cost benefits of Inflation Reduction Act as drugmakers sue government
Health
Biden administration pushes Walgreens, CVS and Walmart to tout drug cost benefits of Inflation Reduction Act as drugmakers sue government
By Riley Griffin and BloombergJuly 19, 2023
NYSE trader
Finance
The A.I. mania is so red hot that a small $50 million investment from Nvidia sent an obscure biotech firm’s shares up a record 78%
By Angel Adegbesan and BloombergJuly 12, 2023
woman at mirror
Health
Ozempic isn’t alone. A whole class of ‘revolutionary’ weight-loss drugs is on the market—but only for the wealthy
By Rachel ShinJuly 9, 2023
Eli Lilly’s CEO pinpoints the 3-prong problem big execs face with remote work
Success
Eli Lilly’s CEO pinpoints the 3-prong problem big execs face with remote work
By Jane ThierJune 24, 2023
Ozempic is pictured in a pharmacy on April 13, 2023 in Niesky, Germany.
Features
The maker of Ozempic and Wegovy is researching groundbreaking new drugs to stop people from becoming obese in the first place
By Vivienne WaltJune 21, 2023
The ADHD drug shortage is spreading as supplies of a popular alternative to Adderall run worryingly low
Health
The ADHD drug shortage is spreading as supplies of a popular alternative to Adderall run worryingly low
By Ike Swetlitz and BloombergJune 20, 2023
Paul Hudson
Success
Gen Z needs brand-new skills to climb to the C-suite: ‘What got me here will not get them there,’ says health care CEO
By Jane ThierJune 2, 2023
GSK’s CEO says you need thick skin if you’re going to step into the C-suite
Leadership
GSK’s CEO says you need thick skin if you’re going to step into the C-suite
By Fortune EditorsMay 31, 2023
Why the underestimated economic burden of rare diseases could be costing the U.S. trillions of dollars
Commentary
Why the underestimated economic burden of rare diseases could be costing the U.S. trillions of dollars
By Giacomo ChiesiMay 25, 2023
A pharmacist waiting on a customer at a pharmacy counter
Health
A Colorado panel of medical and pharmacy experts will decide whose medicine to make affordable this summer
By Markian Hawryluk and KFF Health NewsMay 22, 2023
Sanofi CEO: ‘Europe’s lead in life sciences R&D is eroding–but co-localized hubs could allow it to keep up’
Commentary
Sanofi CEO: ‘Europe’s lead in life sciences R&D is eroding–but co-localized hubs could allow it to keep up’
By Paul HudsonMay 17, 2023
FDA
Health
First-of-its-kind drug for rare form of Lou Gehrig’s disease gets FDA approval
By Matthew Perrone and The Associated PressApril 25, 2023
1...
  • 19
  • 20
  • 21
  • 22
  • 23
...100
Most Popular
Success
Philanthropy leader at Warren Buffett and Bill Gates’ Giving Pledge says children of billionaires are pushing them to give their wealth away fasterplaceholder alt text
By Preston ForeSeptember 20, 2026
Success
'Skills nobody can take': Meet a 20-year-old with a 4.5 GPA who skipped college for technical school to land an 'AI-proof' careerplaceholder alt text
By Muskaan ArshadSeptember 22, 2026
Middle East
China suffers another setback in effort to de-dollarize global finance as anchor in the greenback's dominance quietly exits Beijing's payment schemeplaceholder alt text
By Jason MaSeptember 21, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.